- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07677280
A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products
A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products (Glo and Glo Plus)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Montgomery Hedgecock
- Número de telefone: 336-741-3761
- E-mail: montgomery_hedgecock@rjrt.com
Locais de estudo
-
-
-
Cheshunt, Reino Unido
- Cheshunt Community Sports Park
-
Sheffield, Reino Unido
- Channing Hall
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Ability to read, understand, and be willing to sign an ICF and complete questionnaires written in English.
- Generally healthy male or female, between age 21-65 years (inclusive at the time of consent), verified with government-issued identification.
- All female (assigned at birth) candidate participants and those who identify as "intersex" or "unknown" during screening who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.
- Self-report currently smoking at least five CPD on smoking days in the past 30 days.
- Smoke CC on at least 27 days out of last 30 days.
- Have smoked at least 100 factory-made filtered CC in their lifetime prior to SEV.
- Indicate a willingness to use an HTP.
- Agree to participate in the study and to abide by the study restrictions and requirements, including the use of the assigned Study IP, as described in the ICF.
- Agree not to allow any other person to use any product provided to them for use during this study.
Exclusion Criteria:
- Female participants who self-report they are pregnant or breastfeeding or could become pregnant or start breastfeeding in the next 6 months from the study start date.
Women who self-report they are not intending to use adequate contraception methods to prevent pregnancy.
a) Examples of acceptable contraception methods are, but not limited to: i. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy); ii. Established use of oral, implantable, injectable, or transdermal methods of contraception associated with inhibition of ovulation; iii. Physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide; iv. Non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena); v. Vasectomized partner; vi. Abstinence from heterosexual intercourse (as a lifestyle choice, not just for the purpose of study participation); and vii. Post-menopausal who are not on hormone replacement therapy.
- Males who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or to refrain from donating sperm from the time of signing the informed consent until the EOS, unless they have undergone a vasectomy or were abstinent from heterosexual intercourse, or their female partner was not able to bear children.
- Individuals who self-report having pacemakers or other embedded electronic medical devices.
- Individuals who self-report having an unstable heart condition, severe hypertension or diabetes.
- Individuals who self-report they are sensitive to nicotine.
- Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
- Individuals who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
- Individuals who are employed by a company that manufactures tobacco, HTPs, marketing or in ongoing litigation with a tobacco company.
- Individuals who self-report that they are planning to quit all nicotine products in the next three months.
- Individuals who are personally, have household members, or have close family or friends in ongoing or past litigation with a company that manufactures tobacco or HTPs.
- People who have taken part in a tobacco/nicotine research study in the past 30 days.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: HTP Device 1
|
Tobacco Flavor
Menthol Flavor
|
|
Experimental: HTP Device 2
|
Tobacco Flavor
Menthol Flavor
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To measure the puffing topography of primary CC smokers when using either the glo or glo plus device with one of two stick variants during a five-day use period.
Prazo: 5 days
|
The primary endpoints of this study will be measured in using built-in topography measures and the product use behavior (PUB) instrument (Study Arm 1 only). The data will include:
|
5 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Determine the frequency of use of the glo and glo plus devices in Standard and Boost Mode
Prazo: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the frequency of use of the glo plus pen detached from the charger pack (Study Arm 2 only)
Prazo: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the average daily consumption (ADC) of CC smoked, sticks consumed, and other TNPs used
Prazo: 5 days
|
Through self-reported questionnaires
|
5 days
|
|
Determine overall product liking and purchase intent
Prazo: 5 days
|
Overall Product Liking: 1 (Strongly Dislike) - 10 (Strongly Like) Purchase Intent: 1 (Definitely would not purchase) - 10 (Definitely would purchase)
|
5 days
|
|
Characterize demographic characteristics
Prazo: 5 days
|
5 days
|
|
|
Determine the safety profile (i.e., adverse events/experiences [AEs]) of the Study IP
Prazo: 5 days
|
5 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Melissa Tapia, Ph.D., RAIS Company
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- PHI252503
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .